no code implementations • 30 Jun 2019 • Niranjan Balachandar, Christine Liu, Winston Wang
The current state of cancer therapeutics has been moving away from one-size-fits-all cytotoxic chemotherapy, and towards a more individualized and specific approach involving the targeting of each tumor's genetic vulnerabilities.
